Watanabe K, Murakami S, Misago M, et al. Sjögren\'s syndrome concurrent with protein‐losing gastroenteropathy with secondary systemic capillary leak syndrome : A case report. Clin Case Rep. 2018;6:1829--1833. 10.1002/ccr3.1675

1. INTRODUCTION {#ccr31675-sec-0001}
===============

Protein‐losing gastroenteropathy is a rare condition. In some cases, it has been found to coexist with connective tissue diseases, such as Sjögren\'s syndrome.[1](#ccr31675-bib-0001){ref-type="ref"} We experienced the case of a patient with Sjögren\'s syndrome concurrent with protein‐losing gastroenteropathy who subsequently developed secondary systemic capillary leak syndrome, making their condition temporarily critical. However, the combination of various treatments resulted in an improvement. Here, we report the first case of Sjögren\'s syndrome concurrent with protein‐losing gastroenteropathy in which secondary systemic capillary leak syndrome developed, together with a review of the literature.

2. CASE HISTORY {#ccr31675-sec-0002}
===============

The patient was an 88‐year‐old man with a history of dyslipidemia, right corneal transplantation, and cataract surgery. One month prior to hospitalization, he experienced respiratory distress on exertion and pedal edema, for which he consulted his local physician. Upon receiving a diuretic, Chinese herbal medicine, and albumin drip infusion, his symptoms improved. One week prior to hospitalization, the patient experienced abdominal bloating and was referred to our hospital after being diagnosed with pleural effusion with ascites; he was subsequently hospitalized.

On admission, the patient\'s height was 155 cm and weight was 62.2 kg, and he presented with mild edema of the fingers and marked fast pitting edema in both legs. Laboratory tests on admission revealed hypoalbuminemia, with 2.8 g/dL Albumin (Table [1](#ccr31675-tbl-0001){ref-type="table"}). However, as the urinary protein/creatinine ratio was 0.926 g/g Creatinine, nephrotic syndrome was ruled out.

###### 

Blood tests results

                                               Initial
  -------------------------------------------- ----------
  Hemoglobin (g/dL)                            11.3
  Hematocrit (%)                               34.0
  Mean corpuscular volume (fL)                 85.9
  Platelets (×10^9^/L)                         254
  Leukocytes (×10^9^/L)                        6.7
  Neutrophils (×10^9^/L)                       3.5
  Lymphocytes (×10^9^/L)                       2.4
  Prothrombin time ratio (INR)                 1.03
  D‐dimers (μg/mL)                             3.8
  Uric acid (mg/dL)                            4.4
  Blood urea nitrogen (mg/dL)                  22
  Creatinine (mg/dL)                           0.75
  Total protein (g/dL)                         5.8
  Albumin (g/dL)                               2.8
  Total bilirubin (mg/dL)                      0.4
  AST (IU/L)                                   28
  ALT (IU/L)                                   11
  Alkaline phosphatase (IU/L)                  227
  LDH (IU/L)                                   210
  Total cholesterol (mg/dL)                    211
  Sodium (mEq/L)                               133
  Potassium (mEq/L)                            3.9
  Chloride (mEq/L)                             102
  Calcium (mg/dL)                              8.2
  Creatine phosphokinase (IU/L)                63
  CRP (mg/dL)                                  2.3
  TSH (μU/mL)                                  3.4
  BNP (pg/mL)                                  88.2
  Interleukin‐6 (pg/mL)                        25.2
  Vascular endothelial growth factor (pg/mL)   179
  Gamma globulin (g/dL)                        0.91
  IgG4 (mg/dL)                                 48
  Anti‐SS‐A antibody                           Positive
  Anti‐SS‐B antibody                           Positive
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As platelet count was normal and abdominal ultrasonography revealed no sign of liver cirrhosis, liver failure was also ruled out. Heart failure and hypothyroidism were also ruled out. Pleural effusin test revealed exudative, with 83 IU/L LDH and 3.5 g/dL protein, but it was modified according to infusing albumin by physician who treated him before the admission. So, actually pleural effusion seemed to be transudative.

Contrast‐enhanced computed tomography of the chest and abdomen revealed lymph node edema of \<1 cm in the bilateral axilla and mediastinum.

A right axillary lymph node biopsy was normal and laboratory tests revealed mildly elevated levels of interleukin‐6 at 25.2 pg/mL, vascular endothelial growth factor (VEGF) at 179 pg/mL, gamma globulin at 0.91 g/dL, CRP at 2.3 mg/dL, and IgG4 at 48.0 mg/dL (Table [1](#ccr31675-tbl-0001){ref-type="table"}); thus, Castleman disease was ruled out. Serum positivity for anti‐SS‐A and anti‐SS‐B antibodies (Table [1](#ccr31675-tbl-0001){ref-type="table"}), as well as an ocular staining score of \>4 points in both eyes, indicated that the subject satisfied 2 out of 3 items of the 2012 classification for Sjögren\'s syndrome established by the American College of Rheumatology and The Sjögren\'s International Collaborative Clinical Alliance; thus, the patient was diagnosed with Sjögren\'s syndrome.[2](#ccr31675-bib-0002){ref-type="ref"} Furthermore, gum test revealed dry mouth, with a saliva flow rate of 0.5 mL/10 min.

Biopsies of the stomach, duodenum, rectum, skin, abdominal wall fat, and bone marrow were performed; however, since amyloid deposition was not observed, amyloidosis was ruled out. Biopsies of the stomach and duodenum showed only mild lymphangiectasis. Immunologic studies to assess complements were not performed.

Fecal fat staining was negative. However, technetium‐99 m‐labeled human serum albumin scintigraphy revealed early radioisotope accumulation in the small bowel (Figure [1](#ccr31675-fig-0001){ref-type="fig"}). Because of this typical finding of protein‐losing gastroenteropathy and absence of gastrointestinal bleeding, we diagnosed protein‐losing gastroenteropathy.

![Technetium‐99 m‐labelled (^99m^Tc‐labelled) human serum albumin (HSA) scintigraphy. 2 minutes after intravaenous injection of ^99m^Tc‐labelled HSA, there was mild accumulation in the small bowel, and it became clear. 3 hours and 30 minutes after injection, there was movement of accumulation in the anus side. Typical features of protein losing gastroenteropathy were documented](CCR3-6-1829-g001){#ccr31675-fig-0001}

Fecal alpha‐1‐antitrypsin test was useful but unavailable at our hospital.

3. OUTCOME {#ccr31675-sec-0003}
==========

On day 18 of hospitalization, a dose of prednisolone at 30 mg/d (0.5 mg/kg/d) was initiated. On day 24, a sudden drop in blood pressure, reduced level of consciousness, elevated level of hematocrit (Ht) at 48.3%, pleural effusion with ascites, pericardial effusion, systemic edema and decreased level of serum albumin at 1.7 g/dL were observed. This led to a suspicion of protein leakage from a location other than the gastrointestinal tract, and upon diagnosis of secondary systemic capillary leak syndrome,[3](#ccr31675-bib-0003){ref-type="ref"} human gamma globulin at a dose of 0.4 g/kg/d was administered for 5 days. Because the improvement in edema was poor, the dosage of prednisolone was increased to 50 mg/d starting on day 16; however, the patient showed little response to this increase in dosage of prednisolone. From day 28 to day 30, steroid pulse therapy was administered with methylprednisolone at 1 g/d and theophylline therapy was simultaneously initiated and maintained at a serum concentration of 10‐20 μg/mL. On day 31, his body weight reached its maximum value of 71.2 kg (9.0 kg increase since admission), and prednisolone was recommenced at 50 mg/day. From day 32 to day 42, 20% albumin at 100 mL/d and furosemide at 20 mg/d were administered. As a result, his body weight gradually decreased and the edema also improved. On day 45, theophylline was discontinued, and the dosage of prednisolone was reduced on days 46, 61, and 75 to 40 mg/d, 30 mg/d, and 25 mg/d, respectively. On day 80, he was discharged from the hospital, and he subsequently continues to receive treatment on an outpatient basis.

4. DISCUSSION {#ccr31675-sec-0004}
=============

Autoimmume diseases that cause protein‐losing gastroenteropathy include scleroderma, systemic lupus erythematosus, Sjögren\'s syndrome, rheumatoid arthritis, mixed connective tissue disease, and dermatomyositis, and the cause of protein‐losing gastroenteropathy associated with autoimmune disease is thought to be related to capillary hyperpermeability.[1](#ccr31675-bib-0001){ref-type="ref"} Among autoimmune diseases, there have been 21 published reports from 1988 to 2017 in English and Japanese of cases presenting with Sjögren\'s syndrome concurrent with protein‐losing gastroenteropathy, as in the present case (Table [2](#ccr31675-tbl-0002){ref-type="table"}).[1](#ccr31675-bib-0001){ref-type="ref"}, [4](#ccr31675-bib-0004){ref-type="ref"}, [5](#ccr31675-bib-0005){ref-type="ref"}, [6](#ccr31675-bib-0006){ref-type="ref"}, [7](#ccr31675-bib-0007){ref-type="ref"}, [8](#ccr31675-bib-0008){ref-type="ref"}, [9](#ccr31675-bib-0009){ref-type="ref"}, [10](#ccr31675-bib-0010){ref-type="ref"}, [11](#ccr31675-bib-0011){ref-type="ref"}, [12](#ccr31675-bib-0012){ref-type="ref"}, [13](#ccr31675-bib-0013){ref-type="ref"}, [14](#ccr31675-bib-0014){ref-type="ref"}, [15](#ccr31675-bib-0015){ref-type="ref"}, [16](#ccr31675-bib-0016){ref-type="ref"}, [17](#ccr31675-bib-0017){ref-type="ref"}, [18](#ccr31675-bib-0018){ref-type="ref"}, [19](#ccr31675-bib-0019){ref-type="ref"}, [20](#ccr31675-bib-0020){ref-type="ref"}, [21](#ccr31675-bib-0021){ref-type="ref"}, [22](#ccr31675-bib-0022){ref-type="ref"}, [23](#ccr31675-bib-0023){ref-type="ref"} Among such publications, there are no reports of secondary systemic capillary leak syndrome, thereby making our case the first case to be reported.

###### 

The previous reports of PLGE patients associated with SS

  Author             Publish year   Age   Sex   Nationality     Alb (g/dL)   SS‐A   SS‐B   ANA    Complication              Steroid                                                Other therapy              Outcome   Reference
  ------------------ -------------- ----- ----- --------------- ------------ ------ ------ ------ ------------------------- ------------------------------------------------------ -------------------------- --------- ----------------------------------------------------------------------------------
  Sugiyama T         1988           47    F     Japanese        1.6          \+     ‐      64     Chronic thyroiditis       PSL 60 mg (p.o.)                                                                  Improve   [1](#ccr31675-bib-0001){ref-type="ref"}, [4](#ccr31675-bib-0004){ref-type="ref"}
  Yamada H           1994           38    F     Japanese        2.3          ND     ND     ND     SLE                       PSL                                                                               Improve   [5](#ccr31675-bib-0005){ref-type="ref"}
  Iizuka H           1996           28    F     Japanese        1.4          ND     ND     ND     Chronic thyroiditis       PSL 40 mg                                                                         Improve   [6](#ccr31675-bib-0006){ref-type="ref"}
  Inoue R            1996           49    F     Japanese        2.4          ND     ND     ND     n.p.                      PSL 40 mg                                                                         Improve   [7](#ccr31675-bib-0007){ref-type="ref"}
  Mok MY             1997           54    F     ‐               1.4          ND     ND     ND     ‐                         PSL 60 mg (p.o.)                                       CPA 100 mg                 Improve   [8](#ccr31675-bib-0008){ref-type="ref"}
  Imai K             2002           64    F     Japanese        2.7          \+     \+     ND     RA                        ‐                                                      Ubai‐en (Kampo medicine)   Improve   [9](#ccr31675-bib-0009){ref-type="ref"}
  Hsieh TY (case1)   2002           37    F     Taiwanese       1.4          \+     ND     320    n.p.                      m‐PSL 750 mg × 3 d 2course (i.v.) + PSL 30 mg (p.o.)   HCQ 200 mg                 Improve   [10](#ccr31675-bib-0010){ref-type="ref"}
  Hsieh TY (case2)   2002           50    F     Taiwanese       1.1          \+     ND     640    n.p.                      m‐PSL 750 mg × 3 d 3course (i.v.) + PSL 30 mg (p.o.)   HCQ 200 mg                 Improve   [10](#ccr31675-bib-0010){ref-type="ref"}
  Choi HJ            2004           50    F     Korean          ND           ND     ND     ND     ND                        PSL 60 mg (p.o.)                                                                  Improve   [11](#ccr31675-bib-0011){ref-type="ref"}
  Ushiyama A         2004           61    F     Japanese        1.8          \+     ‐      320    Chronic thyroiditis       PSL 40 mg (i.v.)                                                                  Improve   [12](#ccr31675-bib-0012){ref-type="ref"}
  Nagashima T        2009           41    M     Japanese        1.3          \+     \+     1280   n.p.                      PSL 70 mg (i.v.) + m‐PSL 1 g × 3 d (i.v.)                                         Improve   [13](#ccr31675-bib-0013){ref-type="ref"}
  Nasu T             2011           59    F     Japanese        2.8          \+     ‐      ND     RA, Chronic thyroiditis   PSL 50 mg (p.o.) + m‐PSL1 g × 3 d 2course (i.v.)       CPA pulse + MZR 150 mg     Improve   [14](#ccr31675-bib-0014){ref-type="ref"}
  Uraoka Y           2012           42    F     Japanese        1.5          \+     ND     ND     n.p.                      m‐PSL 1000 mg×3 d (i.v.) + PSL 20 mg (p.o.)            CPA pulse + rituximab      Improve   [15](#ccr31675-bib-0015){ref-type="ref"}
  Kakigao K          2012           58    F     Japanese        1.5          \+     ‐      ND     MCTD, hypothyroidism      PSL 45 mg (p.o.)                                                                  Improve   [16](#ccr31675-bib-0016){ref-type="ref"}
  Chen HY            2013           69    F     Chinese         ND           \+     \+     ND     ND                        PSL (p.o.) + m‐PSL (i.v.)                                                         Improve   [17](#ccr31675-bib-0017){ref-type="ref"}
  Yamashita H        2014           51    F     Japanese        1.5          \+     \+     2560   Interstitial pneumonia    PSL 60 mg (p.o.)                                                                  Improve   [18](#ccr31675-bib-0018){ref-type="ref"}
  Liao CY            2015           30    F     Taiwanese       1.8          \+     ND     5120   n.p.                      PSL 30 mg (p.o.)                                       HCQ 400 mg                 Improve   [19](#ccr31675-bib-0019){ref-type="ref"}
  Gupta A            2015           58    F     White           2.6          \+     \+     1280   Type 1 RTA                PSL 60 mg (p.o.)                                       CPA 800 mg/mo                        [20](#ccr31675-bib-0020){ref-type="ref"}
  Izumi Y            2016           64    F     Japanese        3.0          \+     ‐      ‐      n.p.                      PSL 50 mg (p.o.) + m‐PSL 500 mg × 3 d (i.v.)           MZR 200 mg                 Improve   [21](#ccr31675-bib-0021){ref-type="ref"}
  Ofuji K            2016           73    M     Japanese        2.7          \+     ‐      80     Dermatomyositis           PSL 45 mg (p.o.)                                                                  Improve   [22](#ccr31675-bib-0022){ref-type="ref"}
  Hadigal S          2017           67    M     United States   2.5          \+     ND     640    Pleural effusion          PSL                                                    HCQ                        Improve   [23](#ccr31675-bib-0023){ref-type="ref"}
  This case          2018           88    M     Japanese        2.8          \+     \+     40     n.p.                      PSL 30 mg (p.o.) + m‐PSL 1000 mg (i.v.)                IVIG 20 g + theophylline   Improve   

PLGE, protein‐losing gastroenteropathy; SS, Sjögren\'s syndrome; SS‐A, Anti SS‐A antibody; SS‐B, Anti SS‐B antibody; ANA, Anti nuclear antibody; PSL, prednisolone, p.o., per os.; SLE, systemic lupus erythematosus; n.p., not particular; CPA, cyclophosphamide; ND, no data; RA, rheumatoid arthritis; m‐PSL, methylprednisolone; HCQ, hydroxychloroquine; MZR, mizoribine; IVIG, intravenous immunoglobulin; i.v., intravenous; MCTD, mixed connective tissue disease; RTA, renal tubular acidosis.
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Among the 21 reported cases, 18 were females and 19 were reported from East Asia. The present case is also considered a rare case, as the patient is elderly and male. Among the 21 patients reported, 20 received prednisolone, and in the event of a poor response to steroids, additional treatment was administered (eg, cyclophosphamide, hydroxychloroquine, mizoribine, and rituximab), resulting in the alleviation of symptoms in all patients.

In the present case, a sudden drop in blood pressure and hemoconcentration were observed on day 24. Moreover, pleural effusion with ascites, pericardial effusion, and systemic edema were observed. Thus, protein leak other than that from the gastrointestinal tract was suspected, leading to the diagnosis of secondary systemic capillary leak syndrome.

Systemic capillary leak syndrome is a rare disease characterized by 3 features, comprising hypotension, hypoalbuminemia, and hemoconcentration, and is said to cause disruption of vascular endothelial cells, resulting in the leakage of plasma proteins into the interstitial compartment. Because of normal blood pressure and no sign of hemoconcentration on admission, systemic capillary leak syndrome did not present on admission.

The involvement of VEGF has been suggested in the extravascular leakage of protein associated with systemic capillary leak syndrome. Moreover, because our patient also presented with elevated levels of VEGF, VEGF appears to be involved. There has been a reported case of systemic capillary leak syndrome treated with high‐dose intravenous immunoglobulin therapy (IVIG), theophylline therapy (blood concentration at 15‐25 μg/mL), terbutaline (beta‐2 receptor agonist), anti‐human‐TNF‐alpha monoclonal antibodies, and anti‐VEGF antibodies.[3](#ccr31675-bib-0003){ref-type="ref"}

Although our patient was first treated with prednisolone at a dose of 30 mg/d for protein‐losing gastroenteropathy, he later developed secondary systemic capillary leak syndrome, and thus IVIG was administered at a dose of 0.4 g/kg for 5 days, a regimen that is also considered to be a valid treatment for Sjögren\'s syndrome. Upon completion of IVIG therapy, there was no clear therapeutic effect, and additional treatment with steroid pule therapy and theophylline therapy were administered, which successfully alleviated the symptoms. However, it is unclear whether the steroid, IVIG, or theophylline therapy was effective.

In conclusion, we report the case of a patient who presented with Sjögren\'s syndrome concurrent with protein‐losing gastroenteropathy and whose condition became severe upon developing secondary systemic capillary leak syndrome. However, the patient\'s condition was immediately identified, and he recovered with the simultaneous administration of treatment for Sjögren\'s syndrome and systemic capillary leak syndrome.
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